- Home
- MOBX vs CUE Comparison
MOBX vs CUE Comparison
Compare MOBX & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MOBX | CUE |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United States | United States |
| Employees | 46 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6M | 27.1M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | MOBX | CUE |
|---|---|---|
| Price | $0.18 | $0.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 16.7M | 366.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 35.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,287,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 69.16 |
| 52 Week Low | $0.13 | $0.23 |
| 52 Week High | $1.44 | $1.21 |
Technical Indicators
Market Signals| Indicator | MOBX | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 42.37 | 39.68 |
| Support Level | $0.17 | $0.28 |
| Resistance Level | $0.34 | $0.36 |
| Average True Range (ATR) | 0.02 | 0.02 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 49.74 | 25.81 |
Price Performance
Historical ComparisonAbout MOBX Mobix Labs Inc.
Mobix Labs Inc designs, develops and sells components and systems for wireless and wired connectivity, radio frequency (RF), switching and electromagnetic interference (EMI) filtering technologies. Its wireless systems solutions include products for RF and millimeter wave (mmWave) communications, mmWave imaging, software defined radio and custom RF integrated circuits (ICs) targeting the defense, aerospace, commercial and industrial sectors. The majority of the company's revenue is derived from product sales to equipment manufacturers. Geographically, it generates the maximum revenue from the United States.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.